Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676532 | 0.90 | TSHR (0.54) | TSHRKCNH2AKR1C3ALDH1A1MAPT | |
| SCHEMBL25285565 | 0.89 | EPHX1 (0.60) | TSHRKCNH2AKR1C3ALDH1A1MAPT | |
| SCHEMBL291412 | 0.88 | TSHR (0.59) | TSHRKCNH2AKR1C3ALDH1A1MAPT | |
| SCHEMBL31398832 | 0.87 | EPHX1 (0.58) | TSHRKCNH2AKR1C3ALDH1A1MAPT | |
| SCHEMBL21434977 | 0.87 | EPHX1 (0.58) | TSHRKCNH2AKR1C3ALDH1A1MAPT | |
| SCHEMBL9676461 | 0.85 | TSHR (0.56) | TSHRKCNH2AKR1C3ALDH1A1MAPT | |
| SCHEMBL1282588 | 0.85 | TSHR (0.56) | TSHRKCNH2ALDH1A1MAPTMEN1 | |
| SCHEMBL9316221 | 0.85 | TSHR (0.56) | TSHRKCNH2ALDH1A1MAPTKCNJ1 | |
| SCHEMBL5182834 | 0.85 | TSHR (0.56) | TSHRKCNH2AKR1C3ALDH1A1MAPT | |
| SCHEMBL32684923 | 0.83 | MEN1 (0.62) | TSHRKCNH2ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104109235-A | Mono-functionalized polyethylene glycol with nitrogen atom branched center and its preparation method and biologically-relevant matter | XIAMEN SINOPEG BIOTECH CO LTD | 2014-10-22 | — | — | CN | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | JESCHKE PETER | 2006-08-03 | — | — | US | disclosed |
| US-7034130-B2 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-04-25 | — | — | US | disclosed |
| CN-1556802-A | Process for preparing novel spinosyn derivatives | �ݶ�ũ�����ѧ�ɷݹ�˾ | 2004-12-22 | — | — | CN | disclosed |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1412346-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | Bayer CropScience AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003010155-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| US-5470974-A | Uncharged polynucleotide-binding polymers | NEU-GENE DEVELOPMENT GROUP (US) | 1995-11-28 | — | — | US | disclosed |
| US-5142047-A | Morpholino nucleosides for blocking targeted genetic sequence | ANTI-GENE DEVELOPMENT GROUP (US) | 1992-08-25 | — | — | US | disclosed |
| US-4086209-A | Novel nitrogen-containing aromatic polymers and process for their preparation | TEIJIN LIMITED (JA) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | TSHR 4670/4885KCNH2 3751/4885AKR1C3 974/4885 |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | TSHR 3684/4885KCNH2 4632/4885AKR1C3 213/4885 |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | TSHR 3684/4885KCNH2 4632/4885AKR1C3 213/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | TSHR 3614/4885KCNH2 2127/4885AKR1C3 1629/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | TSHR 4670/4885KCNH2 3751/4885AKR1C3 974/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | TSHR 4635/4885KCNH2 4016/4885AKR1C3 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.